Molbio Diagnostics has officially set the price band for its much-anticipated initial public offering at ₹768 to ₹807 per share. The medical technology firm, best known for its portable Truenat platform, is aiming to raise roughly ₹939.70 crore when the subscription window opens on August 10. For retail investors looking to participate, the entry point is set at a minimum investment of ₹14,526 for a single lot of 18 shares.
The Breakdown: Fresh Capital vs. Stake Sale
The structure of the Molbio Diagnostics public issue is heavily weighted toward existing investors cashing out. Out of the total ₹939.70 crore issue size, a significant portion comes via an Offer for Sale, totaling 91.66 lakh equity shares. This OFS involves stake sales from promoter entities like Exxora Trading and Dr. Chandrasekhar Bhaskaran Nair, alongside corporate shareholders such as the India Business Excellence Fund.
However, the company will also raise ₹200 crore in fresh capital. This is a critical detail because it dictates how the company plans to fuel its next phase of growth. According to the filings, Molbio intends to channel ₹105.5 crore of these fresh proceeds into establishing a new research and development facility and a Centre of Excellence through its subsidiary, Bigtec. Another ₹72.2 crore is earmarked for upgrading plant machinery and equipment at its manufacturing units in Goa and Visakhapatnam.
Diagnostics Sector Context and Valuation
Molbio is entering the market at a time when diagnostics companies command varying valuations based on their specific niches. While traditional pathology labs like Dr. Lal Pathlabs and Metropolis Healthcare trade at price-to-earnings multiples over 60x, Molbio’s focus on point-of-care molecular diagnostics—specifically its battery-operated, PCR-based Truenat systems designed for resource-limited settings—places it in a slightly different category.
Financially, the company has shown robust momentum leading up to this event. For the fiscal year ending March 2026, Molbio reported a 42% year-on-year surge in total income, reaching ₹1,455 crore, up from ₹1,027 crore the previous year. Profit after tax also saw a healthy 18% increase to ₹164 crore. This growth trajectory, driven by testing solutions for diseases ranging from tuberculosis to COVID-19, will be a key focal point for institutional buyers assessing the company’s long-term viability against established peers.
Crucial Dates and Current Market Sentiment
For those tracking the timeline, the core subscription period runs from Monday, August 10, through Wednesday, August 12. Following the close, the basis of allotment is tentatively scheduled to be finalized on Thursday, August 13. Refunds for unsuccessful bids and demat credits should follow by August 14, setting the stage for a targeted listing on both the BSE and NSE on Monday, August 17.
As for the early indicators of market demand, the grey market premium is currently muted. As of the latest checks on August 5, unofficial and unverified market chatter suggests the GMP is sitting at ₹0. This indicates that early off-market trading has not yet priced in a premium over the upper end of the ₹807 price band, though these figures often fluctuate significantly once the subscription officially opens and institutional demand becomes clearer.
Conclusion
With its established presence in rapid molecular diagnostics and strong recent revenue growth, Molbio Diagnostics presents an interesting case within the broader healthcare sector. Investors will now be watching closely to see how the Qualified Institutional Buyers react when the anchor book opens, which often sets the tone for retail participation in the days that follow.
Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk. forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.